Caribou Biosciences files Rule 144 for 6,938 shares

Caribou Biosciences, Inc. submitted a Rule 144 notice relating to 6,938 common shares associated with vesting restricted stock units granted under its equity compensation plan.

Rhea-AI Filing Summary

Caribou Biosciences, Inc. submitted a Rule 144 notice relating to 6,938 common shares associated with vesting restricted stock units granted under its equity compensation plan. The filing lists dates 02/20/2026 (vesting/grant) and 02/24/2026 (filing) and identifies NASDAQ as the market.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 for Caribou Biosciences (CRBU) report?

The Form 144 reports a proposed sale of 6,938 common shares tied to vested restricted stock units. It lists the vesting/grant date as 02/20/2026 and the filing date as 02/24/2026, and names NASDAQ as the market.

Who is the broker or intermediary named on the CRBU Form 144?

The filing names Morgan Stanley Smith Barney LLC at 1 New York Plaza as the broker-dealer. The form shows the intermediary and lists the planned sale under Rule 144 by the reporting party using that broker.

Are the shares from an equity compensation plan in the CRBU filing?

Yes. The Form 144 states the 6,938 shares were granted as part of an issuer equity compensation plan and vested on 02/20/2026. The entry explicitly ties the shares to restricted stock unit vesting.

Does the CRBU Form 144 disclose proceeds or sale timing?

The excerpt does not provide proceeds or confirmed sale timing. It lists the proposed sale under Rule 144 and filing date 02/24/2026, but does not state an aggregate sale price or scheduled transaction dates.

Will this Form 144 filing change CRBU outstanding share counts?

The filing does not state any change to shares outstanding. It reports a proposed resale of 6,938 common shares tied to vested RSUs; outstanding share figures are not provided in the excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/25/2026 - 09:41 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001231321
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CARIBOU BIOSCIENCES, INC.
SEC File Number	001-40631
Address of Issuer	2929 7TH STREET, SUITE 105 BERKELEY CALIFORNIA 94710
Phone	510-982-6030
Name of Person for Whose Account the Securities are To Be Sold	BARBARA G MCCLUNG
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	6938	13598.48	93468038	02/24/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/20/2026	Vesting of Restricted Stock Units	Caribou Biosciences, Inc.			6938	02/20/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	Reflects the number of shares of common stock that were sold in a "sell-to-cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person.
Date of Notice	02/25/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/07/2022
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Barbara G. McClung
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)